Published Date: 26 Apr 2023
More than 90% of people in the world own or use a mobile phone, and many of us couldn't live without them. We carry them everywhere we go, use them in bed and the bathroom, and for many people, they are the first thing they see in the morning.
Read Full NewsUltragenyx seeks FDA accelerated approval for UX111 gene therapy in Sanfilippo syndrome, citing neurologic benefit and the use of cerebral spinal fluid heparan sulfate data.
Here's some of what is coming soon to NeurologyLive® this week.
AGNOS trial showed that monthly treatment with ofatumumab lowered NfL and GFAP in patients with early RRMS, signaling reduced nerve damage and bolstering first-line treatment potential.
Pediatric neurologist Charuta Joshi, MD, discussed global disparities in epilepsy for children and adolescents amid International Epilepsy Day, highlighting opportunities for education, stigma reduction, and improved care access.
The FDA issued a CRL for gene therapy RGX-121 in Hunter syndrome, citing trial design and biomarker doubts; Regenxbio seeks a meeting with the agency and resubmission.
In this interview, Siegel highlights key points presented in his Maui Derm 2026 talk, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'
New Phase 3 Findings Support Ameluz-PDT for Patients with Actinic Keratosis
1.
Analysis of 2021 data shows new cancer diagnoses did not rebound as expected following pandemic
2.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
3.
Heavy Cannabis Use Tied to Increased Head and Neck Cancer Risk
4.
Novel analysis identifies markers that may predict failure of metastatic prostate cancer treatment
5.
Why are so many young adults getting cancer?
1.
Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial
2.
Claudin-18.2 in Gastric Cancer: Tumor-Stroma Crosstalk and Disease Progression
3.
Transfusing the Future: Exploring the Possibilities of Blood Transfusions
4.
A Closer Look at MCV Modules: Features, Functions, and Benefits
5.
Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
5.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation